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ABSTRACT
The Immune Epitope Database (IEDB, www.iedb
.org) provides a catalog of experimentally
characterized B and T cell epitopes, as well as
data on Major Histocompatibility Complex (MHC)
binding and MHC ligand elution experiments. The
database represents the molecular structures
recognized by adaptive immune receptors and the
experimental contexts in which these molecules
were determined to be immune epitopes. Epitopes
recognized in humans, nonhuman primates,
rodents, pigs, cats and all other tested species are
included. Both positive and negative experimental
results are captured. Over the course of 4 years,
the data from 180978 experiments were curated
manually from the literature, which covers 99%
of all publicly available information on peptide
epitopes mapped in infectious agents (excluding
HIV) and 93% of those mapped in allergens. In
addition, data that would otherwise be unavailable
to the public from 129186 experiments were sub-
mitted directly by investigators. The curation of
epitopes related to autoimmunity is expected to be
completed by the end of 2010. The database can be
queried by epitope structure, source organism, MHC
restriction, assay type or host organism, among
other criteria. The database structure, as well as its
querying, browsing and reporting interfaces, was
completely redesigned for the IEDB 2.0 release,
which became publicly available in early 2009.
INTRODUCTION
Established in 2004 as a National Institute of Allergy and
Infections Diseases (NIAID) contract, the Immune
Epitope Database (IEDB) and Analysis Resource can be
found at www.iedb.org. The IEDB makes information on
all experimentally determined immune epitopes freely
available to the public (1,2). Although, many other
epitope-related databases exist (3–11), the IEDB is
unique in its breadth of scope and its ﬁne granularity.
The database presents the epitopes (i.e. the molecular
structures recognized by the receptors of the adaptive
immune system) along with the experimental contexts in
which these molecules were determined to be immune
epitopes. The data are derived from all published
epitope-related data available in PubMed as well as
from direct submissions from scientists experimentally
generating large data sets.
The scope of the database is set by the NIAID and
includes, to date, epitopes related to A–C pathogens,
emerging and reemerging pathogens, other infectious
diseases, allergens and recently autoantigens. Currently,
the database houses nearly all (92%) published experimen-
tal data related to peptidic epitopes from infectious
diseases (excluding HIV) and 89% of those related to
allergens. This represents an unprecedented data set,
allowing end users to quickly and easily know everything
that has ever been published regarding immune epitopes
from a certain pathogen, in a particular host or having a
particular type of experimental result. Data derived from
the database can be used in various applications including,
vaccine development, assay design and disease treatment.
Additionally, the database houses analysis tools related
to immune epitopes (12). These tools complement the
database and allow users to predict potential epitopes
from antigens of interest, or to analyze known epitopes
for population coverage and other relevant applications.
First available online in 2005, the IEDB recently under-
went a major review resulting in signiﬁcant advancements.
Driven by user feedback, curator experience and the devel-
opment of the Ontology of Immune Epitopes (ONTIEs)
(13), data quality was scrutinized and the database schema
was redesigned to accommodate new data types and
features. The redesigned data schema allowed imple-
mentation of formal validation rules, which led to
the identiﬁcation and correction of 693133 validation
inconsistencies. This process that took 28 man months
has resulted in drastically improved data consistency.
These changes also resulted in enhanced usability for the
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improvements. We describe here, in detail, the utility of
the database as well as the advancements made as part of
the IEDB 2.0 release.
Overview of the IEDB
Immune epitopes are the molecular structures recognized
by adaptive immune receptors: T cell receptors (TCRs),
B cell receptors (BCRs) and antibodies. The purpose of
the IEDB is to catalog all experimentally derived informa-
tion on immune epitopes, either as found in published
manuscripts or directly submitted by the scientist
generating the data. Each epitope is linked to its reference
source. For published manuscripts, this information
includes the authors, article title, journal name and
abstract.
The types of data that are included are experiments
describing recognition of an epitope by TCRs (T cell
assays), BCRs or antibodies (B cell assays), as well as
assays characterizing what molecular structures are pres-
ented by MHC molecules to T cells, such as elution of an
epitope from an MHC molecule (MHC ligand elution
assays) or experiments demonstrating the binding of an
epitope to an MHC molecule (MHC binding assays).
The epitope structure, source antigen and organism from
which the epitope is derived are all described. The scope of
the database includes data relating to epitopes derived
from all infectious diseases, including NIAID Category
A, B and C priority pathogens (www3.niaid.nih
.gov/topics/BiodefenseRelated/Biodefense/research/CatA
.html), NIAID Emerging and Reemerging infectious
diseases (www3.niaid.nih.gov/topics/emerging/), allergens,
and autoantigens involved in autoimmune disorders. HIV
epitopes are explicitly excluded, which can instead be
found in the Los Alamos HIV Molecular Immunology
Database (www.hiv.lanl.gov) (14).
Rather than focusing simply on human or mouse
immune responses, the IEDB does not discriminate
against the hosts in which the immune response was
studied, therefore all vertebrate species are potentially
included.
The IEDB is supported by a contract from the
NIAID and is freely available to the public. Feedback
and questions are encouraged and can be sent to
feedback@iedb.org.
Identifying relevant publications through PubMed
The query to extract epitope-related references consists of
multiple epitope-speciﬁc keywords and logical operators.
A Python script runs this query to identify all potentially
relevant references catalogued in PubMed. An automated
text classiﬁer (15) is used to remove a substantial number
of abstracts that are outside the scope of IEDB. This
classiﬁer is a combination of two popular machine
learning methods: Naı¨ve Bayes and support vector
machine (16) and classiﬁes each reference as either
curatable or uncuratable. For each abstract that the
classiﬁer deems as curatable, the full-text manuscript is
then reviewed by IEDB curators and only those
still found to be curatable are entered into the database.
The criteria that make a reference curatable include, but
are not limited to, the presence of epitope-speciﬁc data
and an explicitly deﬁned epitope structure.
Once references have been classiﬁed as curatable, the
subject matter of each publication is categorized
(Table 1). Within each class, we assign a category and
subcategory to further reﬁne the topics included within
the IEDB data set. The number of references present in
each subcategory can be found in Supplemental Table 1.
This information is not only useful to users interested in
what sort of data the IEDB includes but also to scientists
who may want to evaluate the relative abundance or
paucity of epitope-speciﬁc data in a given research area.
Curation of experimental data
Experimental data are entered by a team of PhD level
curators following complex curation guidelines, estab-
lished by the team with the input of immunological
experts (17). These curation rules are constantly
reevaluated in light of new experimental procedures
and are adapted as the scope of the database grows.
They are made available to the end users, in the form
of a curation manual (tools.immuneepitope.org/wiki/
index.php/Curation_Manual2.0), in order to ensure trans-
parency and to encourage feedback. Each curated manu-
script is reviewed for accuracy and adherence to the IEDB
curation guidelines prior to becoming available to external
users. Additionally, a comprehensive review of all curated
data is performed prior to public release.
Acquiring data directly from investigators
In addition to published manuscripts, the IEDB also
contains data that have been directly submitted by
scientists. Typically, submitted data accompany the pub-
lication in which a narrower data set is described. For
direct submissions, the IEDB links all data to the submit-
ting authors, title, abstract and the date of the submission.
Currently, data submitted directly to the IEDB
accounts for 33% of all epitope structures housed in the
database. Data submissions can be made in XML format
or by utilizing a newly developed IEDB Data Submission
Tool (DST). This tool enables users to submit data
utilizing tab-delimited template ﬁles which can be edited
in Microsoft Excel or an equivalent application. This
enhancement has signiﬁcantly streamlined the submission
process for users who are not familiar with the XML
format. Although the submitted data are largely generated
by 14 epitope discovery contract holders (18), all scientists
Table 1. Main categories of peptidic epitope-related references
Main category Total number
of references
% Processed
Allergen 1229 88.9
Autoimmune 4401 26.1
Infectious disease 9085 92.3
Cancer 2697 2.7
HIV 2404 1.4
Transplant/alloantigens 899 3.8
Others 3932 7.2
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sion of their data. Please contact submissionsupport@
iedb.org for more information.
Database design
The IEDB now utilizes ﬁve distinct relational databases
(Figure 1). Three of the ﬁve databases are operational
databases that support the internal curation application
used by the IEDB curators who enter the data. These
three databases are used to store in progress and
completed records and maintain the integrity of the data
throughout the curation process. The remaining two
databases provide data warehousing functionality and
support querying, reporting and analysis activities. The
IEDB Query database is designed using a dimensional
approach that is optimized for querying and reporting
and does not attempt to conform to any level of data
normalization. The IEDB Public database, which is
intended to support data analysis, is designed using a
more normalized approach, though it does not achieve
ﬁrst normal form. Given its more ﬂexible design, the
IEDB Public database, along with its entity relationship
diagram, has been made available for public download in
binary and SQL formats.
IEDB ontology
To facilitate the conversion of experimental data from text
and ﬁgures in a journal publication into a computer-
friendly format, we have developed the ONTIEs
(ontology.iedb.org). ONTIE has been developed as a
module that is imported by the Ontology for Biomedical
Investigations (OBI) (The OBI Consortium http://purl
.obolibrary.org/obo/obi) (19), making it immediately
accessible to a wide user base. Through active ontology
development, the relationships among entities stored in
the database became clear. This was the major impetus
for restructuring the database with a focus on objects,
processes and roles as shown in Figure 2. For example,
a peptide can play the role of epitope when it participates
in the process of an immunological assay. The
restructuring of the database around a central ‘object’
table accommodates these ontological relationships.
Database content
Epitopes. Epitopes are described by two key sets of ﬁelds;
those describing the molecular structure of the epitope and
those describing the source from which the epitope was
derived. The IEDB contains data related to linear peptide
epitopes and also non-peptidic epitopes such as lipids and
carbohydrates. Thus, the chemical type of the epitope is
captured in the ‘Structure Type’ ﬁeld. For linear peptide
epitopes, by far the most commonly encountered type, the
structure of that epitope is described utilizing the ‘Linear
Sequence ﬁeld’. The database also represents non-peptidic
epitopes such as carbohydrate or lipid epitopes utilizing
simpliﬁed molecular input line entry speciﬁcation
structures. The IEDB is currently collaborating with the
Chemical Entities of Biological Interest (ChEBI) project in
order to depict non-peptidic structures with proper
nomenclature, synonyms and 3D structures (20).
In addition to the molecular structure of the epitope, the
natural source (i.e. the ‘Source Organism’) and the molec-
ular source (Source Antigen) of each epitope, as described
by the scientist generating the data are noted. The protein
sources that epitopes are derived from are described by
linking to GenBank records.
The organisms from which epitopes are derived are
described utilizing NCBI Taxonomy (21). The IEDB
refers to the NCBI Taxonomy ID to describe an
organism and also represents the organism within its
place in the taxonomical tree in order to allow the end
user to search via a family of organisms or on an exact
strain. As part of the 2.0 release, the IEDB began supple-
menting the NCBI tree with strains commonly encoun-
tered in immunological research such as inbred mouse
strains and viral isolates. All previously curated data
were mapped to these new strains, when applicable.
These supplemental organisms are also placed within the
NCBI tree structure to allow the same search capabilities.
As a result, users are now able to search on all laboratory
animals tested in the literature.
Figure 1. IEDB database architecture diagram. Data are transferred
between curation databases via custom PL/SQL procedures. Data are
migrated to the data warehouses via SQL and PL/SQL scripts in con-
junction with an extract, transform and load (ETL) application.
Figure 2. Objects, processes and roles as represented in the IEDB.
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The data housed by the IEDB is epitope-centric with every
experimental assay describing the recognition of an
epitope to which the assay is linked. Assays describing
recognition of an epitope by TCRs (T cell assays), BCRs
or antibodies (B cell assays), as well as assays
characterizing MHC presentation, such as elution of an
epitope from an MHC molecule (MHC ligand elution
assays) or experiments demonstrating the binding of an
epitope to an MHC molecule (MHC binding assays) are
included in the database.
Immunization
In B cell and T cell assays, the immunization procedure
whereby the host became exposed to the immunogen is
captured. First, the ‘Host Organism’ in which the
exposure occurred is entered by its taxonomy ID.
Additional host information is captured including age,
sex, disease state and disease stage at the time of the exper-
imental assay when provided by the authors. The disease
state of the host is currently described utilizing the ICD-10
classiﬁcation of diseases (www.who.int/classiﬁcations/
icd/en/).
Next, the ‘in vivo Process Type ﬁeld’ describes how the
host organism came to be exposed to the immunogen in
vivo utilizing a menu of immunization types which are
grouped into the following categories: occurrence of
disease, administration in vivo and exposure not resulting
in disease.
As part of the immunization process, the IEDB
describes the immunogen to which the host was exposed
along with the immunogen’s relationship to the epitope,
the ‘Immunogen Epitope Relation’. For example, if the
assay demonstrates the recognition of an epitope derived
from inﬂuenza by antisera from an inﬂuenza-infected
human, the immunogen that the host was exposed to
was the inﬂuenza virus. The epitope being studied is
derived from the inﬂuenza virus, thus the ‘Immunogen
Epitope Relation’ is the epitope’s ‘Source Organism’.
This relationship provides the end user with additional
information regarding the context in which the epitope
is recognized.
Additionally, the certainty of the curator that the entity
being entered is the immunogen and is provided via the
new ‘Immunogen Evidence Code’. This code expresses
whether the author was explicit in specifying to what the
host was exposed. For example when a speciﬁc strain of a
virus is injected into an animal, the ‘Immunogen Evidence
Code’ would be ‘Exact Match’ versus when an author is
vague regarding the immunogen, as with humans exposed
to an unknown strain of inﬂuenza it would be
‘Representative Selection’.
For all procedures that involved administration of the
immunogen to the host, the route, dose schedule and
adjuvants utilized are also captured.
The IEDB describes up to two in vivo immunizations, as
is common in animals ﬁrst infected with a virus and then
boosted with a peptide or in humans vaccinated with
a peptide vaccine and then exposed to the virus the
vaccine was meant to protect against. In addition, the
system can describe the in vitro immunogen in the case
of primary induction of eﬀector T cells from naı¨ve
donors or in vitro restimulation procedures performed
on T cells prior to the assay.
Immunological assays
The assay types present within the IEDB reﬂect the assays
being used in the literature. This list includes all
commonly used immunological methods such as ELISA,
FACs, bioassays, etc. and expands to accommodate new
assays as they are developed. For all assay types, the
IEDB uses an assay ﬁnder application that allows users
to search on either the purpose of the assay (to measure
IL-2) or the method used (ELISA). All experimental data
entered into the IEDB are categorized as either positive
or negative in the ‘Qualitative Measurement’ ﬁeld.
Additional granularity is available for positive data with
values of positive-high, positive-intermediate and positive-
low. For assay types with quantitative measurements, such
as the KD between an antibody and epitope, the numerical
values are entered along with the units. When available,
the number of subjects tested, the number responding or
the percent responding are also displayed.
In T cell and B cell assays, the eﬀector cells or the
antibody containing material derived from the host and
being assayed is described. Eﬀector cells are described by
their tissue of origin, cell type and cell culture state at the
time of the experiment. For example, blood, lymphocyte
and direct ex vivo, respectively. For antibody containing
material, the source of the material (for example, serum),
puriﬁcation state (for example, puriﬁed immunoglobulin),
isotype and whether the antibodies are monoclonal or
polyclonal are all captured.
In T cell assays, the antigen-presenting cells (APCs) and
the restricting MHC molecule are also depicted. APCs are
described similarly to the eﬀector cells, utilizing a cell type
drop down list that includes all commonly studied cell
lines. The restricting MHC molecule is displayed along
with an evidence code that illustrates how the restriction
was determined, either in the published reference being
curated or if known by the authors at the onset of the
study.
For every curated experiment, there must be an assay
antigen and a qualitative outcome. The assay antigen is
deﬁned as the recall antigen to which the immune response
is being measured in the experimental context. The exper-
iment may be performed in vitro (e.g. an ELISA) or in vivo
(e.g. a challenge assay). As is done with the immunogen,
the full description of the molecule or organism is
described along with the ‘Antigen Epitope Relation’ for
each antigen. Similar to the immunogen, an ‘Antigen
Evidence Code’ is also used to describe how certain the
curator is of the object being used as the antigen.
A new feature that was added in the 2.0 version of the
IEDB is the ability to describe adoptive transfer
experiments. These are procedures where the eﬀector
material (antibodies or T cells) generated in one
organism (the donor) is transferred to a separate
organism (the recipient) for further study. In these cases,
both the donor and recipient organisms are described as
Nucleic Acids Research, 2010,Vol.38, Database issue D857mentioned for the host above. Additionally, the eﬀector
material that is transferred is explained in detail.
MHC binding assays are those in which an epitope is
demonstrated to bind to a puriﬁed or cell-bound MHC
molecule. MHC ligand elution assays are those that dem-
onstrate the ability of an APC to process and present an
epitope on its surface in the context of an MHC molecule.
As part of the 2.0 release, all previously curated MHC
molecules were edited to be represented by consistent
nomenclature and reorganized by their source organism,
restriction level, haplotype, class, locus, serotype and
molecule name. This was a signiﬁcant undertaking as the
older literature used an inconsistent nomenclature. In
addition, representative protein sequences were provided
for alleles whenever possible. The resulting MHC allele
table now provides more accurate data, more detailed
information on each allele and allows for enhanced
search options.
THE QUERY INTERFACE
The most commonly used search functionality is now
highly visible on the IEDB home page where users can
directly search on criteria such as the epitope structure,
source antigen, source organism or the context in which it
was recognized (Figure 3). Three example queries are
demonstrated in the Supplementary Data. As the same
peptide may be present in many proteins from many
organisms, the IEDB allows users to search on just the
peptide sequence alone (Supplementary Figure 1).
Additionally, data on every epitope derived from a partic-
ular protein can be queried using a protein name,
organism name, chemical type or GenBank identiﬁer
(Supplementary Figure 2). All data generated on every
epitope derived from a certain organism can also be
retrieved (Supplementary Figure 3).
The search interface also allows users to limit
their query to relevant immune recognition contexts
(Figure 3E). For example, a user may be interested in
MHC binding and T cell assays, but not B cell assays.
The host of the immune response (Figure 3F) may be
queried by either the common or scientiﬁc name and by
very narrow criteria, such as an exact strain, or by
selecting any level of the NCBI tree such as all
mammals, as shown in Figure 4. All common names
and synonyms can be viewed by mousing over the scien-
tiﬁc name present within the taxonomical tree.
The ﬁelds ‘MHC Restriction’ and ‘MHC Class’
(Figure 3G and H) can be used to search on the MHC
molecules involved in the epitope’s recognition. One can
search on all T cell data known to be restricted by a
speciﬁc MHC molecule or narrow the search to look for
epitopes recognized in the context of MHC Class I or
MHC Class II subsets.
Table 2 demonstrates how search results are now pres-
ented in a succinct table format. Here the details of the
assay are summarized by providing information on the
epitope, the host of the assay, the immunization proce-
dure, the antigen that was tested in the assay and the
assay type. Every column can be sorted and all blue text
or numbers are links to details pages.
Advanced search functionality
All ﬁelds of the database are searchable and can be found
by utilizing the ‘Search’ dropdown menu on the home
page and further reﬁning the assay type of interest. Once
in the advanced search pages, the user is shown a newly
developed collapsed view of all of the IEDB ﬁelds, display-
ing key ﬁeld groups such as Epitope, Immunization and
Assay (Figure 5). Within each section, the most commonly
searched ﬁelds are displayed with all ﬁelds available
simply by clicking open the section. These pages are
organized following the same structure as the assays them-
selves, for consistency, and are collapsed based upon
usage, for eﬃciency. A complete example of a detailed
search can be found in Supplementary Figure 4. The
IEDB also provides tutorials on searching which can be
found at tutorials.iedb.org.
Browsing by MHC allele or source organism
In addition to the simple and advanced search interfaces,
the homepage provides a keyword search option and
‘browse by’ links, either by MHC allele or by source
organism. When browsing by MHC allele, one is shown
the currently curated data on MHC alleles organized
utilizing the NCBI taxonomy and a hierarchy of MHC
types. For example, if one is interested in human alleles
and clicks on the Homo sapiens icon, the number of Class
I, Class II and non-classical structures for which data
exists are displayed. Within each category, the data are
further organized by their locus, serotype and molecule.
When browsing by source organism, the data are
Figure 3. Home page search. The search ﬁelds are organized into those
describing the epitope structure and source (A–D) and the immune
recognition context (E–H).
D858 Nucleic AcidsResearch, 2010, Vol.38,Database issueorganized following the NCBI taxonomy and allows the
user to search for a particular organism by either common
or scientiﬁc name. Once a search result has been found,
the user has the option of directly viewing the data related
to their search or to view their results within the
taxonomical tree, allowing one to either broaden the
search to a higher node or to reﬁne it by selecting a
speciﬁc strain. In addition, the number of epitopes
derived from each source organism is provided in the
tree to help the user better identify relevant results.
DATA AVAILABILITY
The IEDB is found at www.iedb.org and is organized into
three sections; query interface, up to date metrics on
database content and links to resources.
The IEDB is freely available online and allows users to
export their search results in Microsoft Excel format. The
data can be exported in either a compact or detailed
format. Additionally, users may also download an
export of the schema, tables or the entire database in
either XML or MySQL formats.
SUPPORT
At the new Solutions Center (iedb.zendesk.com/portal),
one will ﬁnd online and downloadable documents
describing the database, the new features of the 2.0
release, the IEDB monthly newsletter and forums discuss-
ing topics that end users have asked about. In addition,
the site provides users with detailed information on how
the IEDB staﬀ curates references and how to query the
database. A shorter version of the curation manual,
tailored for the database user, is provided at tools.immu-
neepitope.org/wiki/index.php/Data_Field_Descriptions.
Links to provide feedback, questions and suggestions are
also present (help@iedb.org).
OUTLOOK FOR THE IEDB AND ITS USERS
The content of the IEDB is current regarding all published
peptidic epitope data relating to infectious disease and
allergens. Within the next year, we expect to complete
the curation of autoimmune-related epitopes and to
bring non-peptidic epitope data into the database. In
order to remain current on new publications, the IEDB
reruns the PubMed query quarterly and adds all new
relevant publications. New data submissions are ongoing
and we expect to increase their number as NIAID
contracts requiring data submission are fulﬁlled.
Additionally, the new DST aﬀords greater access to the
submission process for all scientists wishing to deposit
their data in the IEDB. As new data are entered, the
IEDB continues to adapt data ﬁelds, reevaluate curation
guidelines and seek feedback from end users.
Figure 4. Host organism search. After entering the common name of ‘mouse’, the Organism Finder returns the scientiﬁc name of Mus musculus. The
user can decide to select any higher level of the taxonomical tree, such as Rodentia (the synonym list is displayed when mousing over) or can further
reﬁne the search by selecting a speciﬁc strain.
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D860 Nucleic AcidsResearch, 2010, Vol.38,Database issueImmunology is a constantly expanding ﬁeld and the
database and ontology will continue to evolve in parallel
as new assays are developed or new nomenclature is imple-
mented. The IEDB will continue to expand its collabora-
tion with other resources. The ability to link to other
databases was implemented as part of the 2.0 release,
allowing external databases to directly link to relevant
information present on our web site. We hope this
feature will become widely used as we continue to reach
out to new resources.
The IEDB will continue solicitation of feedback from
users in order to continue improving all aspects of the
database. We are eager for scientists to visit iedb.org
and let us know what you think help@iedb.org.
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